Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Alkermes' (ALKS) Nemvaleukin Alfa Granted FDA Fast Track Designation
August 2, 2021 2:03 PM EDTOn August 2nd, 2021, Alkermes plc (Nasdaq: ALKS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin) - the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, for the treatment of mucosal... More
